Article

<i>Listeria monocytogenes</i> personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens

2020-05-13

Abstract excerpt

<h4>Background</h4> Recent advances in the field of cancer immunotherapy have identified CD8 + T cell responses against tumor-specific mutations as a key driver of tumor regression and overall survival. ADXS-NEO is a personalized Listeria monocytogenes ( Lm )-based immunotherapy designed to target a patient’s mutation-derived tumor-specific neoantigens. The objective of this study is to demonstrate the feasibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: eb0ff711-0a82-5415-8325-56604d9b0e4a
DOI: 10.1101/2020.05.11.088930

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>Listeria monocytogenes</i> personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigensDOI 10.1101/2020.05.11.088930Read

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity Read

An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.Semantic proximity Read

Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity Read

Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver MetastasesSemantic proximity Read

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read

Immunotherapy for ovarian cancer is improved by tumor-targeted delivery of a neoantigen surrogateSemantic proximity Read

Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell LymphomaSemantic proximity Read

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in miceSemantic proximity Read

<i>Enterococcus</i> peptidoglycan remodeling promotes immune checkpoint inhibitor therapySemantic proximity Read

A machine learning model that identifies neoantigen-reactive CD8+ T cells in human gastrointestinal cancerSemantic proximity Read

Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor controlSemantic proximity Read